Ufp Technologies (UFPT) AI Stock Analysis

• Market Cap: $1.81B
• Dividend Yield: N/A
• Average Volume (3M): 237.88K
• Price to Earnings (P/E): 29.1
• Beta (1Y): 1.46
• Revenue Growth: 34.43%
• EPS Growth: 31.90%
• Country: US
• Employees: 4,146
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Devices
• EPS (TTM): 2.47
• Shares Outstanding: 7,706,825
• 10 Day Avg. Volume: 450,019
• 30 Day Avg. Volume: 237,883
• PEG Ratio: 0.13
• Price to Book (P/B): 3.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 224.95
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: 0.49
• Enterprise Value/Gross Profit: 5.94
• Enterprise Value/Ebitda: 2.62
• 1Y Price Target: $252.00
• Price Target Upside: 6.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 82 Outperform
• Price Target: $277.00 ▲(16.74%Upside)

UFPT's overall stock score is bolstered by strong financial performance and positive earnings call results, driven by significant growth in the medical business and successful strategic initiatives. While technical analysis suggests moderate market sentiment, the relatively high valuation and lack of dividend yield are drawbacks. The stock is well-positioned for growth, but potential investors should be mindful of the valuation and sector-specific challenges.

Positive Factors

Acquisitions

Management noted the recent acquisitions are performing ahead of expectations, with AJR being particularly strong.

Financial Performance

UFP Technologies reported revenue, AEBITDA, and EPS above estimates for the fourth consecutive quarter, showing strong outperformance.

Growth Potential

The company is launching two major programs and has a robust pipeline of new business.

Negative Factors

Acquisition Risks

UFP remains on the lookout for other potential targets, which could lead to potential acquisition risks.

Market Expansion Challenges

Ireland-based AQF, while providing inroads into the European market, may face integration challenges.

Ufp Technologies Business Overview & Revenue Model

Company Description

UFP Technologies, Inc. designs and custom manufactures components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics primarily for the medical market. Its single-use and single-patient devices and components are used in a range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging. The company also provides engineered products and components to customers in the automotive, aerospace and defense, consumer, electronics, and industrial markets, which are applied in military uniform and gear components, automotive interior trim, athletic padding, environmentally protective packaging, air filtration, abrasive nail files, and protective cases and inserts. It markets and sells its products in the United States principally through a direct sales force, as well as independent manufacturer representatives. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

How the Company Makes Money

UFP Technologies generates revenue primarily through the design and manufacturing of customized components and packaging solutions. The company's key revenue streams include sales of its products to the medical sector, which encompasses medical devices and disposables, as well as the automotive, electronics, and consumer markets. Significant partnerships with major industry players allow UFP Technologies to maintain a steady flow of contracts and projects. The company's ability to innovate and provide tailored solutions that meet specific client needs is a crucial factor in its financial success.

Ufp Technologies Financial Statement Overview

Summary

UFPT exhibits strong financial performance with significant revenue growth, solid profitability margins, and a stable balance sheet with low leverage. Effective cash flow management further strengthens its financial health, positioning the company well for future growth in the medical devices industry.

Income Statement

UFPT has demonstrated strong revenue growth with a significant increase from $400.1M in 2023 to $547.6M in TTM, resulting in a revenue growth rate of 8.56%. The gross profit margin stands at 28.99%, indicating effective cost management. The net profit margin improved to 11.59%, reflecting enhanced operational efficiency. Both EBIT and EBITDA margins are robust at 16.31% and 18.47% respectively, showcasing strong profitability.

Balance Sheet

The company maintains a solid financial position with a debt-to-equity ratio of 0.046, indicating low leverage. The return on equity is impressive at 17.6%, reflecting high efficiency in using shareholder equity to generate profits. An equity ratio of 56.13% suggests a strong equity base and financial stability.

Cash Flow

UFPT's free cash flow growth rate is 3.64%, demonstrating positive cash generation. The operating cash flow to net income ratio is 1.1, indicating healthy cash generation relative to income. The free cash flow to net income ratio stands at 0.93, confirming efficient cash flow management.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
547.56M	504.42M	400.07M	353.79M	206.32M	179.37M
	Gross Profit
158.76M	146.69M	112.22M	90.26M	51.11M	44.68M
	EBIT
89.28M	80.90M	57.66M	21.64M	21.22M	8.56M
	EBITDA
101.14M	95.80M	68.95M	56.35M	30.04M	25.46M
	Net Income Common Stockholders
63.47M	58.98M	44.92M	41.79M	15.89M	13.37M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
14.03M	13.45M	5.26M	4.45M	11.12M	24.23M
	Total Assets
642.64M	629.00M	404.14M	377.54M	334.13M	203.20M
	Total Debt
16.63M	206.03M	46.04M	55.00M	84.36M	2.21M
	Net Debt
2.60M	192.58M	40.77M	50.55M	73.24M	-22.03M
	Total Liabilities
281.97M	286.24M	118.05M	140.00M	139.69M	26.31M
	Stockholders Equity
360.67M	342.76M	286.09M	237.54M	194.45M	176.89M
Cash Flow		Free Cash Flow
59.01M	56.94M	30.84M	3.96M	8.90M	20.67M
	Operating Cash Flow
69.75M	66.59M	41.33M	17.74M	14.29M	25.04M
	Investing Cash Flow
-211.25M	-210.16M	-10.49M	1.29M	-101.46M	-4.26M
	Financing Cash Flow
144.41M	152.39M	-30.02M	-25.89M	74.05M	-285.00K

Ufp Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 237.27
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UFPT, the sentiment is Positive. The current price of 237.27 is below the 20-day moving average (MA) of 237.48, above the 50-day MA of 222.24, and below the 200-day MA of 263.27, indicating a neutral trend. The MACD of 3.44 indicates Positive momentum. The RSI at 53.77 is Neutral, neither overbought nor oversold. The STOCH value of 47.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UFPT.

Ufp Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UFPT	82 Outperform	$1.81B	29.06	19.36%	―	34.43%	31.90%
CNMD	72 Outperform	$1.84B	15.56	12.96%	1.40%	4.20%	43.62%
AHCO	63 Neutral	$1.18B	15.50	5.12%	―	-0.05%	―
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
IART	52 Neutral	$997.05M	―	-1.85%	―	6.19%	-174.69%
ATEC	51 Neutral	$1.78B	―	-291.71%	―	25.53%	23.22%
TNDM	50 Neutral	$1.49B	―	-92.31%	―	27.65%	-28.22%

Ufp Technologies Corporate Events

UFP Technologies Highlights Strategic Focus on Medical Market

UFP Technologies has released updated presentation materials for investor meetings, highlighting their strategic focus on expanding in the medical device market. The company emphasizes its expertise in design, materials, and global manufacturing, aiming to shift its business towards higher-margin opportunities and expand its presence in the medical, aerospace, defense, and other markets. This move is expected to strengthen UFP’s market positioning and enhance its growth potential, although investors are cautioned about the risks and uncertainties associated with forward-looking statements.

The most recent analyst rating on (UFPT) stock is a Buy with a $300.00 price target. To see the full list of analyst forecasts on Ufp Technologies stock, see the UFPT Stock Forecast page.

UFP Technologies Holds Annual Stockholders Meeting

On June 4, 2025, UFP Technologies held its Annual Meeting of Stockholders where several key proposals were voted on. The stockholders elected seven directors to serve until the 2026 Annual Meeting, approved executive compensation, decided on the frequency of future votes on executive compensation, and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for 2025.

The most recent analyst rating on (UFPT) stock is a Buy with a $344.00 price target. To see the full list of analyst forecasts on Ufp Technologies stock, see the UFPT Stock Forecast page.